Interferon in Liver Diseases: Recent Advances.

IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Yuting Gao, Yuhang Yin, Pengpeng Xie, Deyu Zhang, Hongyu Li, Xingshun Qi
{"title":"Interferon in Liver Diseases: Recent Advances.","authors":"Yuting Gao, Yuhang Yin, Pengpeng Xie, Deyu Zhang, Hongyu Li, Xingshun Qi","doi":"10.1007/s12325-025-03291-8","DOIUrl":null,"url":null,"abstract":"<p><p>Interferons (IFNs) are a pivotal class of cytokines with multifaceted roles in antiviral defense, immune regulation, and antitumor activity. Structural and functional distinctions among IFN types (I, II, and III) underlie their diverse biological effects. IFN production is initiated by pattern recognition receptor signaling, containing Toll-like receptors, RIG-I-like receptors, and the cGAS-STING axis, which activates downstream pathways, such as JAK-STAT, PI3K-AKT, NF-κB, and MAPK signaling pathways. These pathways critically influence the pathogenesis, progression, therapeutic management, and prognosis of liver diseases. This review delineates the mechanistic roles of IFN-associated signaling in viral hepatitis, non-alcoholic fatty liver disease, alcohol-associated liver disease, liver fibrosis, and hepatocellular carcinoma. We further elucidate IFN-mediated regulatory networks in viral defense, metabolic dysregulation, immune responses, and inflammatory activation. By integrating these insights, the review provides a novel therapeutic direction to unravel context-specific IFN dynamics and address unmet needs in the management of liver diseases, thereby fostering personalized approaches to improve clinical outcomes.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03291-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Interferons (IFNs) are a pivotal class of cytokines with multifaceted roles in antiviral defense, immune regulation, and antitumor activity. Structural and functional distinctions among IFN types (I, II, and III) underlie their diverse biological effects. IFN production is initiated by pattern recognition receptor signaling, containing Toll-like receptors, RIG-I-like receptors, and the cGAS-STING axis, which activates downstream pathways, such as JAK-STAT, PI3K-AKT, NF-κB, and MAPK signaling pathways. These pathways critically influence the pathogenesis, progression, therapeutic management, and prognosis of liver diseases. This review delineates the mechanistic roles of IFN-associated signaling in viral hepatitis, non-alcoholic fatty liver disease, alcohol-associated liver disease, liver fibrosis, and hepatocellular carcinoma. We further elucidate IFN-mediated regulatory networks in viral defense, metabolic dysregulation, immune responses, and inflammatory activation. By integrating these insights, the review provides a novel therapeutic direction to unravel context-specific IFN dynamics and address unmet needs in the management of liver diseases, thereby fostering personalized approaches to improve clinical outcomes.

干扰素在肝脏疾病中的研究进展
干扰素(ifn)是一类关键的细胞因子,在抗病毒防御、免疫调节和抗肿瘤活性方面具有多方面的作用。IFN类型(I、II和III)之间的结构和功能差异是其不同生物效应的基础。IFN的产生由模式识别受体信号启动,包括toll样受体、rig - i样受体和cGAS-STING轴,激活下游通路,如JAK-STAT、PI3K-AKT、NF-κB和MAPK信号通路。这些途径严重影响肝脏疾病的发病机制、进展、治疗管理和预后。本文综述了ifn相关信号在病毒性肝炎、非酒精性脂肪性肝病、酒精相关性肝病、肝纤维化和肝细胞癌中的机制作用。我们进一步阐明了ifn介导的病毒防御、代谢失调、免疫反应和炎症激活的调节网络。通过整合这些见解,该综述提供了一个新的治疗方向,以揭示特定环境的IFN动态,并解决肝脏疾病管理中未满足的需求,从而促进个性化的方法来改善临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Therapy
Advances in Therapy 医学-药学
CiteScore
7.20
自引率
2.60%
发文量
353
审稿时长
6-12 weeks
期刊介绍: Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信